The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

For a 45-year-old who pays out of pocket for Wegovy, the cost comes to $3,900 a year - even with the discounts. For a Medicare beneficiary, that cost will be $600 a year in copays. But some research ...

Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early October. The 50-day moving average is a short-term indicator ...

HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.

A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history.

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs could put it back on the right track. While profit margins may slip due to ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

Zepbound (tirzepatide) is a brand-name injection prescribed for weight loss, weight management, and more. You may need to take Zepbound for several months to see the full effects of the drug for ...